Korat-Farang.com

Scancell cancer vaccines

Roger · 67 · 6547

0 Members and 1 Guest are viewing this topic.

Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
As I see my average 17p per share investment in Scancell at 5.6p, here's what we have in this Company now.

Stolen from my colleagues Crumbs and Ray Pointer, in the LSE chatroom, here's a list - bearing in mind that when the SCIB1 melanoma vaccine was still in Phase 2 trial, on the morning that the 'serendipitous' discovery of Moditope was announced, the price soared to 60 pence or more inside a few hours :-

''I know it's been done before but a comparison of the MCAP at its peak some time after Moditope was announced

GBP 100 million post Moditope announcement with :-

No SCIB1 trial results
Moditope announced . . . . . . . .

**************************************

Now GBP 23 million with :-

Immunobody
SCIB1 outstanding results
Patents complete
SCIB1 combo trial starts soon (we hope)
SCIB2 combo trial funded by CRUK (probably starting next year)
Glioblastoma vaccine collaboration

Moditope
Patents almost complete for citrullinated targets
Modi trial starts soon (we hope)
Addition of amplivant to Moditope
Modi2 may now be in development
Collaboration with Biontech for 2 targets on TCR going well
Appointment of TCR specialist scientist
Collaboration with Karolinska

Glycans
Patent process underway

Scientific endorsements
Peer review of SCIB1 trial
SCIB1 combo trial managed by Keith Flaherty
CRUK funding of SCIB2 combo trial
Project blueprint team members
BionTech collaboration
Karolinska collaboration
Lindy winning Waldenström award

And finally, (Prof.) Lindy is asking the question :-


http://www.portlandpresspublishing.com/sites/default/files/biochemist/Biochemist%20Immunology%20issue/BioFEB19Web_Choudhury%29.pdf  ''

Plenty of news to come. Meantime . . . as my old Pal Spargo says in Cornwall, ''can't help poverty Boy".

 
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
My 'ailing' investment (SCLP) stands at 7.25 pence per share now   :-\ 
But here's a most impressive slide show on World Cancer day. Really worth a look if you have time.

Immuno-Oncology is changing the world of cancer treatment and little Scancell now has 3 platforms and three products going into trial this year.

https://www.scancell.co.uk/Data/Sites/1/media/docspres/presentation-to-lsx-world-congress-february-2020.pdf
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
My 'ailing' investment (SCLP) stands at 7.95 pence per share now, after hitting 3.6 pence recently (but 64 pence in 2012)  :-\  Trial progress has been interrupted but Scancell announced this week that they have a project for a CV-19 vaccine . .

https://www.scancell.co.uk/development-of-vaccine-against-covid-19

In Today's Times, (Prof. Lindy Durrant is CSO of Scancell) :-

"British researchers are entering the race to develop a Covid-19 vaccine by modifying an existing cancer therapy. The candidate vaccine, under development at Nottingham University, would focus on stimulating elements of the immune system called T-cells, which scientists suspect hold the key to longer-term immunity. Human trials could be held in the autumn.

Lindy Durrant, a professor of cancer immunotherapy at Nottingham, has developed a technique where DNA is injected into patients to create T-cells that recognise and destroy cancer cells. Her team are modifying the technique to produce T-cells that attack and kill cells that have been infiltrated. “Most vaccines stimulate strong neutralising antibodies but weak T-cell responses. Although this is good enough for many viruses, for coronaviruses it seems that strong T-cell responses are also required,” Professor Durrant said.

Discussion around the development of a Covid-19 jab has focused on antibodies, proteins that stick to the virus and prevent it from entering cells. However, scientists believe that T-cells are critical. “It’s interesting that in Sars [another coronavirus] the long-term immunity is all T-cells, not the antibodies,” said Sir John Bell, regius professor of medicine at Oxford. “The antibodies go away after two years. But the speculation is that you can still have residual T-cell reactivity for about five or six years.” Sir John added that a candidate vaccine being developed at Oxford, which went into human trials last week, had been designed to produce both antibodies and a T-cell response.

The Nottingham vaccine will take a different approach. It will contain pieces of DNA that should enter the nuclei of the muscle cells into which it is injected. This will provide the instruction for the cells to produce two types of protein. One is from the nucleocapsid of the virus that causes Covid-19 — the spherical container that holds its genetic material. The other is from the spikes that protrude from the surface of the virus, which it uses to latch on to and invade human cells. Several other vaccines, including Oxford’s and one being developed at Imperial College, focus on the spike protein. However, Professor Durrant suspects that the nucleocapsid protein will induce a more potent T-cell response. It is also similar across most types of coronavirus, which could make it useful for a range of pathogens. “These T-cells may also give protection against other related coronaviruses and any new ones that may arise in the future,” she said
."

https://www.thetimes.co.uk/article/fad1c73e-8be7-11ea-8030-261bf7d8ac38?shareToken=8137ff5c9ed028980d50788834e42db6
« Last Edit: May 02, 2020, 04:46:30 PM by Roger »
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
From a poster on a 'Scancell' forum . . . "I still think that the Scancell approach looks to be the most interesting. Has anyone seen mention of another approach that uses both Antibodies and TCells to neutralise the virus? The fact that studies are beginning to indicate that people who have recovered have long lasting memory TCells but only weak antibody protection is IMO significant. Here's an article about the SARS coronavirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362397/

And from a more recent article about covid19 . . "“Antibodies are not the only answer,” says Iwasaki. “We don’t know why the people recovered but I suspect it was because they had a very good T cell response.”
The sample size in this study was small, so whether that ratio of convalescent patients with and without antibodies scales up to the larger population remains to be seen."
https://www.bbc.com/future/article/20200421-will-we-ever-be-immune-to-covid-19

Back to Immunobody. This has probably been posted a number of times but it is well worth a read for those new to Scancell " As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest." And . . "“Vaccines are the long-term solution and we believe our combined high avidity T cell and neutralizing antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to COVID-19,” said Professor Lindy Durrant, Chief Scientific Officer Scancell." https://www.scancell.co.uk/immunobody

ME - I hope that's of interest. Nice weekend to you . . .
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
The DM is rightly much maligned for it's gossip/celebrity obsessions but it does do some things very well. A section 'AND THERE IS A CANCER LINK' in this article strikes some chords. Scancell is onto this chain already . . .

"The immune system has two lines of defence: innate immunity, which includes 'natural killer' and other types of cell that are on the lookout for any bacteria, virus or fungus which might look foreign; and the adaptive or acquired immune system. This second type of defence is a set of more specialised cells, unique to each of us, that has developed over our lifetime to recognise and destroy any invader that has tried to attack our body in the past. Covid-19 only emerged at the end of last year, so human immune systems have never been exposed to it and have no prepared defences. Our bodies, therefore, have to rely on innate immunity — natural killer and so-called T-cells, along with other types of defence cells."

https://www.dailymail.co.uk/health/article-8308883/Is-inflammation-link-dementia-cancer-coronavirus.html

''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
Hi Caller. Can you get behind the paywall in the "Times'? When you have time, could you please do a search for Prof. Lindy Durrant (Scancell's CSO) as there is comment there today on Scancell's CV-19 'Covidity' project with the two Nottingham Unis. Thanks.
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein


Online Roger

  • KFers beyond Korat
  • Forum Wizard
  • *****
    • Posts: 3980
In the 'Sunday People' (?) - "The researchers led by Professor Lindy Durrant, are testing on mice and human trials could begin in the Autumn if funding is secured. Prof Durrant SAID: " The technology is there because our vaccine came from cancer patients. As soon as we have more data in mice, we can move to humans. If you have good T cell memory it should last longer. It could potentially last 5 to 6 years."

A full explanation of Scancell's 'Covidity' project and worth a full read IF you are interested . . . A vaccine maybe giving 'years' of immunity   ;D

"Scancell Holdings plc, (Oxford, UK), a developer of novel immunotherapies for the treatment of cancer, has initiated a research program to develop a novel DNA vaccine for COVID-19. The research program will be in collaboration with scientists from the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham (Nottingham, UK) and Nottingham Trent University (Nottingham, UK).

Scancell's DNA vaccines target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells. This approach was highly successful with Scancell's lead ImmunoBody cancer vaccine, SCIB1, which was safely administered to patients with malignant melanoma, and mediated excellent five-year survival in a Phase 1/2 clinical trial. Scancell's aim is to utilize its proven clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralizing antibodies (VNAbs) against COVID-19. As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells
."

https://www.hospimedica.com/covid-19/articles/294782018/dna-based-vaccine-could-deliver-potent-and-long-lasting-responses-to-covid-19.html
''If you can't explain it simply, you don't understand it well enough'' - Albert Einstein